Kostas Biliouris Analyst Performance

Biotech Equity Analyst at BMO Capital Markets

Kostas Biliouris is a stock analyst at BMO Capital Markets in the medical sector, covering 11 publicly traded companies. Over the past year, Kostas Biliouris has issued 14 stock ratings, including buy and hold recommendations. While full access to Kostas Biliouris' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kostas Biliouris' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 15 Last 3 Years
Buy Recommendations: 60.00% 9 Buy Ratings
Companies Covered: 11 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	60.0%	9 ratings
Hold	40.0%	6 ratings
Sell	0.0%	0 ratings

Out of 15 total stock ratings issued by Kostas Biliouris at BMO Capital Markets, the majority (60.0%) have been Buy recommendations, followed by 40.0% Hold.

Best & Worst Calls

Best Call
000.0%
LEGN
Jul 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	11 companies

Kostas Biliouris, an analyst at BMO Capital Markets, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 11 companies	100.0%

Kostas Biliouris of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	63.6%
MED - DRUGS 4 companies	36.4%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ALNY Alnylam Pharmaceuticals	9/5/2025	Boost Price Target	$453.40	$470.00	Outperform
IONS Ionis Pharmaceuticals	9/3/2025	Upgrade	$57.49	$70.00	Outperform
SRPT Sarepta Therapeutics	7/29/2025	Boost Price Target	$16.75	$50.00	Market Perform
SRPT Sarepta Therapeutics	7/21/2025	Lower Price Target	$14.07	$50.00	Market Perform
JSPR Jasper Therapeutics	7/8/2025	Reiterated Rating	$3.04		Market Perform
VERV Verve Therapeutics	6/27/2025	Reiterated Rating	$11.29	$13.50	Market Perform
ALNY Alnylam Pharmaceuticals	6/24/2025	Boost Price Target	$323.26	$360.00	Outperform
SRPT Sarepta Therapeutics	6/16/2025	Downgrade	$36.18	$70.00	Market Perform
RNA Avidity Biosciences	3/12/2025	Initiated Coverage	$29.58	$72.00	Outperform
DYN Dyne Therapeutics	3/12/2025	Initiated Coverage	$12.03	$50.00	Outperform
RCKT Rocket Pharmaceuticals	3/12/2025	Initiated Coverage	$8.21	$50.00	Outperform
SLN Silence Therapeutics	3/4/2025	Lower Price Target	$4.56	$25.00	Outperform
IONS Ionis Pharmaceuticals	2/20/2025	Lower Price Target	$31.29	$45.00	Market Perform
NTLA Intellia Therapeutics	1/10/2025	Lower Price Target	$11.50	$50.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.